B-Tg(Luc) LNCap Clone FGC

• 322217

B-Tg(Luc) LNCap Clone FGC

Product nameB-Tg(Luc) LNCap Clone FGC
Catalog number322217
TissueProstate
DiseaseCarcinoma

このページで

  • Description
  • Phenotypic analysis
  • Tumorigenicity
  • Efficacy

ポスター

すべて表示

    出版物

      Description
      • Origin: The LNCaP clone FGC cell line displays characteristic epithelial morphology. It was established in 1977 through needle aspiration of a metastatic left supraclavicular lymph node from a 50-year-old Caucasian male patient (blood type B+) diagnosed with advanced prostate cancer. This cellular model serves as a valuable resource for oncology research.
      • Background Information: Luciferase-expressing cell lines are genetically engineered to produce luciferase enzymes, typically from fireflies (Photinus pyralis). These bioluminescent reporter systems enable real-time monitoring of cellular processes through light emission when exposed to substrate luciferin. Widely used in molecular biology, they facilitate gene expression studies, drug screening, and in vivo imaging applications.
      • Gene targeting strategy: The exogenous promoter and luciferase coding sequence were randomly inserted into the LNCap Clone FGC cells.
      • Tumorigenicity: Confirmed in B-NDG mice.
      • Application: The B-Tg(Luc) LNCap Clone FGC tumor models can be used to evaluate anti-cancer drugs in Prostate cancer in vivo. It can be applied subcutaneously and orthotopically to prostate in mice.
      In vitro luciferase activity of B-Tg(Luc) LNCap Clone FGC cells

      Luminescence signal intensity of B-Tg(Luc) LNCap Clone FGC cells. Cell lysates of wild-type LNCap Clone FGC and B-Tg(Luc) LNCap Clone FGC were measured using the Bright-GloTM luciferase Assay (Promega, Catalog No. E4030). B-Tg(Luc) LNCap Clone FGC cells have a strong luminescence signal that is not present in wild-type LNCap Clone FGC cells.

      Tumor growth curve & Body weight changes

      Subcutaneous homograft tumor growth of B-Tg(Luc) LNCap Clone FGC cells.  B-Tg(Luc) LNCap Clone FGC cells (2×106) and LNCap Clone FGC cells (2×106) were subcutaneously implanted into B-NDG mice (male, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-Tg(Luc) LNCap Clone FGC cells were able to establish tumors in vivo and can be used for efficacy studies.

      Establishment of orthotopic prostate cancer model

      Establishment of orthotopic prostate cancer model. The mouse orthotopic prostate cancer was generated by implanting B-Tg(Luc) LNCap clone FGC cells in the dorsal prostate lobes of B-NDG mice (male, n=7), and the tumor volume, body weight and signal intensity of the mice were recorded weekly. The results showed that the tumor volume increased and body weight of mice gradually decreased during this study. This indicates that the cell line was successfully constructed as an orthotopic tumor model. H&E staining showed that necrosis and hemorrhage were seen in prostate tumors, and inflammatory cell infiltration can be seen in seminal vesicles(D). Values are expressed as mean ± SEM.